Search

A look at clinical trials underway or in preparation in France and worldwide.

The 10th International Limb-Girdle Muscular Dystrophy (LGMD) Awareness Day takes place on September 30. Organized by the LGMD Awareness Foundation, the day's mission is to draw attention to this group of rare neuromuscular diseases and their impact on the lives of affected children and adults in all regions of the world. 

Alongside the hosts of France Televisions and surrounded by numerous artists, Mika will use all his talent, sensitivity and energy to support families in their fight against rare diseases. Discover his message !

September 21, 2024 marks the 2nd World Myositis Day. At last year's World Myositis Congress in Berlin, international associations fighting inflammatory myopathies decided to dedicate the day to raising public awareness and mobilizing resources around these rare diseases. This worldwide initiative aims to better understand and treat myositis by uniting efforts on a global scale.

September 15, 2024 marks the 4th International Myotonic Dystrophies Awareness Day. This event, supported by over 60 organizations worldwide, aims to raise awareness among the general public, healthcare professionals and political decision-makers of the need to improve diagnosis, care and support for patients, and to speed up the development of medicines. The AFM-Telethon, which brings together French patients affected by these diseases, is committed to speeding up research. This new edition focuses on two specific areas in particular: raising awareness and educating clinical care teams, and preparing participants for clinical trials.

World Duchenne Muscular Dystrophy Day provides an opportunity to note the acceleration in the development of innovative therapies for this neuromuscular disease, which is the most common in children. Gene therapy is one of the most promising avenues. Genethon, the AFM-Telethon laboratory, is currently developing a drug candidate which has demonstrated its efficacy in the first patients to be treated. Discover our video of patient testimonials ! 

On Friday 31 August, 56 people from the Danish association MuskelsVindfonden, the Danish equivalent of AFM-Téléthon, visited the Institut de Myologie.

"Cure through Innovation" is a booklet that sums up the main actions and missions of the AFM-Téléthon association, as well as its key figures for 2023. The July 2024 edition has just been published!

At each Telethon, thousands of volunteers and partners join forces to organize fundraising initiatives all over France and abroad. This participation is unique by its sheer scale.

Since 1987, the Telethon is a nearly thirty hours TV program broadcasted on the France Télévisions' channels. Discover all the ingrediants of the TV show.

Transparent and meticulous management: in 2023, AFM-Telethon committed €93.5 M to its social missions, in addition to €6.9 M in advances and investment for the Cure mission.  

Created in 1987 at the initiative of Bernard Barataud and Pierre Birambeau, both fathers of sons suffering grom Duchenne muscular dystrophy, the Telethon combines, since its first edition, a TV program and dozen of thousands of events throughout France. Discover the birth of this unique fundraising event.  

Treatments and therapeutic innovation are born out of the knowledge of genes and the understanding of the mechanisms causing disease. Beyond its three pioneering laboratories combined within the Biotherapies Institute for rare diseases, AFM-Telethon has been developing collaborations for many years with scientists from all over the world.

Committed to scientific research as well as to the support of patients and their families, AFM-Telethon acts independently, guided only by the urgency of the progressive disease, for the benefit of patients.  

On June 20, World FSHD Day reminds us of the importance of raising awareness and supporting research into facioscapulohumeral muscular dystrophy. Committed to the fight against FSHD, the AFM-Téléthon is making available a series of publications to enlight the advances in research by it, but also by many other neuromuscular diseases.